Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;109:962-965
Published online before print February 23, 2004, doi: 10.1161/01.CIR.0000120505.91348.58
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
109/8/962    most recent
01.CIR.0000120505.91348.58v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikolaidis, L. A.
Right arrow Articles by Shannon, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikolaidis, L. A.
Right arrow Articles by Shannon, R. P.
Related Collections
Right arrow Energy metabolism
Right arrow Type 2 diabetes
Right arrow Catheter-based coronary and valvular interventions: other
Right arrow Acute myocardial infarction

(Circulation. 2004;109:962-965.)
© 2004 American Heart Association, Inc.


Brief Rapid Communications

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Lazaros A. Nikolaidis, MD; Sunil Mankad, MD; George G. Sokos, DO; Glen Miske, DO; Ankur Shah, MD; Dariush Elahi, PhD; Richard P. Shannon, MD

From the Cardiovascular Research Institute, Allegheny General Hospital, Pittsburgh, Pa (L.A.N., S.M., G.G.S., G.M., A.S., R.P.S.), and the University of Massachusetts Medical Center, Worcester, Mass (D.E.).

Correspondence to Dr Richard P. Shannon, Department of Medicine, Allegheny General Hospital, 320 E North Avenue, Pittsburgh, PA 15212. E-mail rshannon{at}wpahs.org

Received October 9, 2003; de novo received November 21, 2003; revision received January 13, 2004; accepted January 14, 2004.

Background— Glucose-insulin-potassium infusions are beneficial in uncomplicated patients with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular (LV) dysfunction because of volume requirements associated with glucose infusion. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimulate glucose uptake without the requirements for concomitant glucose infusion.

Methods and Results— We investigated the safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) <40% after successful primary angioplasty compared with 11 control patients. Echocardiograms were obtained after reperfusion and after the completion of the GLP-1 infusion. Baseline demographics and background therapy were similar, and both groups had severe LV dysfunction at baseline (LVEF=29±2%). GLP-1 significantly improved LVEF (from 29±2% to 39±2%, P<0.01), global wall motion score indexes (1.94±0.11->1.63±0.09, P<0.01), and regional wall motion score indexes (2.53±0.08->2.02±0.11, P<0.01) compared with control subjects. The benefits of GLP-1 were independent of AMI location or history of diabetes. GLP-1 was well tolerated, with only transient gastrointestinal effects.

Conclusions— When added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.


Key Words: myocardial infarction • insulin • heart failure • angioplasty




This article has been cited by other articles:


Home page
CirculationHome page
K. Ban, M. H. Noyan-Ashraf, J. Hoefer, S.-S. Bolz, D. J. Drucker, and M. Husain
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor-Dependent and -Independent Pathways
Circulation, May 6, 2008; 117(18): 2340 - 2350.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. H. Opie
Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia
Circulation, April 29, 2008; 117(17): 2172 - 2177.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
O. Schmitz
The GLP-1 Concept in the Treatment of Type 2 Diabetes--Still Standing at the Gate of Dawn?
J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 375 - 377.
[Full Text] [PDF]


Home page
CirculationHome page
S. E. Inzucchi and D. K. McGuire
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Circulation, January 29, 2008; 117(4): 574 - 584.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Basu, N. Charkoudian, W. Schrage, R. A. Rizza, R. Basu, and M. J. Joyner
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1289 - E1295.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
J. J. Holst
The Physiology of Glucagon-like Peptide 1
Physiol Rev, October 1, 2007; 87(4): 1409 - 1439.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. M. Yellon and D. J. Hausenloy
Myocardial Reperfusion Injury
N. Engl. J. Med., September 13, 2007; 357(11): 1121 - 1135.
[Full Text] [PDF]


Home page
JAMAHome page
S. M. Donahoe, G. C. Stewart, C. H. McCabe, S. Mohanavelu, S. A. Murphy, C. P. Cannon, and E. M. Antman
Diabetes and Mortality Following Acute Coronary Syndromes
JAMA, August 15, 2007; 298(7): 765 - 775.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, Y.-T. Shen, and R. P. Shannon
Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1106 - 1113.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. C. Riddle and D. J. Drucker
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Diabetes Care, February 1, 2006; 29(2): 435 - 449.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. A. Nikolaidis, D. Elahi, Y.-T. Shen, and R. P. Shannon
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2401 - H2408.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Tsang, D. J. Hausenloy, and D. M. Yellon
Myocardial postconditioning: reperfusion injury revisited
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H2 - H7.
[Full Text] [PDF]


Home page
DiabetesHome page
A. K. Bose, M. M. Mocanu, R. D. Carr, C. L. Brand, and D. M. Yellon
Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Diabetes, January 1, 2005; 54(1): 146 - 151.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
L. A. Nikolaidis, A. Doverspike, T. Hentosz, L. Zourelias, Y.-T. Shen, D. Elahi, and R. P. Shannon
Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 303 - 308.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
T. Nystrom, M. K. Gutniak, Q. Zhang, F. Zhang, J. J. Holst, B. Ahren, and A. Sjoholm
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
Am J Physiol Endocrinol Metab, December 1, 2004; 287(6): E1209 - E1215.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Taegtmeyer
Cardiac Metabolism as a Target for the Treatment of Heart Failure
Circulation, August 24, 2004; 110(8): 894 - 896.
[Full Text] [PDF]